In Denver, families face the daily challenge of balancing rent, groceries, and medical expenses. For those living with chronic conditions like autoimmune diseases, this balancing act is even harder. Prescription drugs can cost thousands of dollars. Some can’t keep up. Others make tough choices, like skipping doses to save money.With over 715,000 people in the area, it’s no surprise that the ripple effects of high drug prices run deep.
A Game Changer for Some
Enter the Colorado Prescription Drug Affordability Board. On October 3, they made history by capping the price of Enbrel at $31,000 per year. It’s the first time a state has taken such a step. For many Coloradans facing these high drug costs, it’s a victory. Chloe’s victory.Still, this price cap won’t take effect until 2027. That’s a long wait. For some, too long. Will patients be able to hold on?
Can This Trend Catch On?
Can other states follow Colorado’s lead? That’s the big question.Governor Jared Polis seems to think so. He called this move the “first step.” Still, he’s clear-eyed. Federal support? Still needed. A single state can only do so much.Advocates in Oregon and New York are already watching. Even California has been exploring the idea of a drug affordability board. But the path from interest to action is long. Will these states join in? Some companies are already working to regulate healthcare costs as they are.
What’s Next?
The board has already identified several high-cost drugs for review. Trikafta, a medication for cystic fibrosis, could be next. Colorado previously declined to label it unaffordable. But critics say it’s time to reconsider. For patients who need it, Trikafta is life-changing.Another possibility? Insulin. Life-saving, yet often priced out of reach. Patients across Denver have spoken for years about its cost. Will it face a price cap in the future? Likely. It’s not a question of if, but when.
A Step Forward — But Not Far Enough
Back in Denver, reactions are mixed. Advocates are celebrating. Patients like Chloe feel some relief. But critics warn the fix could be messy. Price caps might lead to fewer suppliers carrying the drug. Access could still be limited.Affordability alone? Only scratches the surface. Some Denver residents still face insurance delays or outright denials.“It’s not perfect,” Chloe admits. “But it’s a start.”Maybe, just maybe, this is a step toward real change — for Denver, for Colorado, and eventually, for the rest of the United States.
Related topics:
